{"domain":"lixte.com","status":"valid","tier":"listed","authority":49,"verified":false,"title":"LIXTE: Transforming cancer treatment with PP2A inhibitors","summary":"Lixte Biotechnology Holdings, Inc\\. \\(Nasdaq: LIXT\\) is a clinical\\-stage pharmaceutical company developing a new class of oncology treatments and cancer therapies called PP2A inhibitors\\.","country":null,"country_source":"cdn","publisher_country":null,"publisher_country_source":null,"hosting_country":null,"llms_txt":"https://lixte.com/llms.txt","llms_full_txt":null,"last_checked":"2026-10-23T23:14:48.400Z","agent_terms":null,"categories":["healthcare","science-research"],"capabilities":[],"inferred_tags":["pp2a inhibitors","oncology drugs","cancer therapy","clinical stage pharma","lixt nasdaq"],"audience":"business","agent_uses":["read_docs"],"language":"en","platform_generated":false,"agent_summary":"LIXTE Biotechnology (Nasdaq: LIXT): clinical-stage pharma developing PP2A inhibitor oncology therapies; site has science references, team and articles.","llms_txt_cached":"https://agentwebmap.com/v1/domain/lixte.com/llms.txt","agentic":"documentation","section_keys":["categories","optional","pages"],"section_partial":false,"section_indexed_at":"2026-10-21T19:10:44.232Z"}